Should CBD-Focused Zynerba Pharmaceuticals Be In Your Portfolio?

Zynerba Pharmaceuticals (ZYNE) is a Devon, Pennsylvania-based specialty pharmaceutical company that develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q deletion syndrome and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).  The company was…

founded in 2007 and was listed on NASDAQ in 2015.

The company’s focus is the cannabidiol (CBD) gel Zygel. In October, the company received a patent on the “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to a method of treating FXS comprising administering 250mg or 500mg of synthetic or purified cannabidiol in a pharmaceutically acceptable carrier. Earlier this month, the company announced plans to review the design and protocol for a new clinical trial through a Type C meeting with the U.S. Food and Drug Administration (FDA) during the first half of 2021, with a new clinical trial commencing before the end of year.

“We believe that Zygel has the potential to meaningfully relieve the behavioral symptoms of the most impacted individuals with Fragile X syndrome,” said Armando Anido, chairman and CEO of Zynerba. “We are thankful for our ongoing constructive dialogue with the FDA on our path forward to NDA [new drug application] submission.”

Although Anido added the company will be concentrating its main efforts on the FXS trial, ZYNE will…

Continue reading at STOCKNEWS.com

 

You May Also Like

About the Author: admin

Leave a Reply

Your email address will not be published.